Erdinc BOZKURT
(Kafkas Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Kars, Türkiye)
Abdullah GUMUS
(Kafkas Üniversitesi, Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Kars, Türkiye)
Yaran KOBAN
(Ersoy Hastanesi, Göz Hastalıkları Anabilim Dalı, İstanbul, Türkiye)
Yıl: 2020Cilt: 29Sayı: 4ISSN: 1300-1256 / 2717-7149Sayfa Aralığı: 318 - 323İngilizce

49 0
Can Serum Endocan Level Predict Stage of Diabetic Retinopathy?
Purpose: We aimed to evaluate the relationship between serum endocan levels and diabetic retinopathy (DR) severity in diabetic patients.Material and Method: The study included 72 patients with diabetes mellitus (DM) and 28 volunteer control patients without any systemic disease. Patients with no systemic disease were the 1st group (n=28), diabetic patient without DR were the 2nd group (n=21), patients with non-proliferative DR were 3rd group (n=24) and patients with proliferative DR were 4th group (n=27). BMI, serum endocan levels, HbA1c, urea, creatinine levels and macular thickness were measured. Results: Serum endocan levels were 170.05±85.67, 333.91±13.41, 340.42±105.07, 472.83±147.40 ng/L, respectively. BMI was 23.11±1.37 in the 1st group, 28.05±4.62 in the 2nd group, 29.00±5.69 in the 3rd group, and 28.85±5.88 in the 4th group. HbA1c levels were 4.83±0.55 in 1st group, 6.60±1.15 in 2nd group, 8.49±1.24 in 3rd group, and 8.89±1.30 in 4th group. Macular thickness measured with OCT was 216.96±11.64, 253.29±23.62, 274.88±61.11, 352.93±120.08μm in the right eye and 218.96±11.93, 240.65±17.57, 283±62.89, 334.78±127.71μm in the left eye, respectively.Conclusion: In our study, there was a relationship between serum endocan level and DR stage. Serum endocan level can reveal important information about the severity and stage of DR such as serum creatinine and HbA1c level. There is a potential need for further research to demonstrate whether endocan is involved in DR pathogenesis.
DergiAraştırma MakalesiErişime Kapalı
  • 1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-36. doi: 10.1016/S0140-6736(09)62124-3.
  • 2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909.
  • 3. Wu L, Fernandez-Loaiza P, Sauma J, et al. Classifi cation of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4:290-4. doi: 10.4239/wjd.v4.i6.290.
  • 4. Menon P, Kocher ON, Aird WC. Endothelial cell specifi c molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation. 2011;124:A15455.
  • 5. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specifi c molecule-1 (ESM- 1): a potential novel endothelial cell marker and a new target or cancer therapy. Biochimica et Biophysica Acta (BBA)- Reviews on Cancer. 2006;1765(1):25-37.
  • 6. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: a novel infl ammatory indicator in cardiovascular disease? Atherosclerosis. 2015;243(1):339-43.
  • 7. Dieterich LC, Mellberg S, Langenkamp E, et al. Transcriptional profi ling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol. 2012;228:378-90. doi: 10.1002/path.4072
  • 8. Lee W, Ku SK, Kim SW, et al. Endocan elicits severe vascular infl ammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-30.
  • 9. Sun H, Zhang H, Li K, et al. ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J Cell Physiol. 2019;234:1512-21
  • 10. Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115:581-90
  • 11. American Diabetes A. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37, 14-S80.
  • 12. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman medical journal. 2012;27(4):269.
  • 13. Bozkurt E, Çakır B, Çelik E. Correlation of the aqueous humor total antioxidant capacity, total oxidant status, and levels of IL-6 and VEGF with diabetic retinopathy status. Arq. Bras. Oftalmol. 2019;82: 136-140.
  • 14. Dhananjayan R, Koundinya KS, Malati T, et al. Endothelial dysfunction in type 2 diabetes mellitus. Indian Journal of Clinical Biochemistry. 2016;31:372-9.
  • 15. Dhananjayan R, Koundinya KS, Malati T, et al. Endothelial dysfunction in type 2 diabetes mellitus. Indian Journal of Clinical Biochemistry. 2016;31:372-9.
  • 16. Aburawi EH, AlKaabi J, Zoubeidi T, et al. Subclinical Infl ammation and Endothelial Dysfunction in Young Patients with Diabetes: A Study from United Arab Emirates. Plos One. 2016;11:e0159808.
  • 17. Bagcier F, Tufanoglu FH, Kadıçeşme Ö. Is There Any Relationship Between Serum Endocan Levels and Carotid Intima-media Thickness in Patients with Fibromyalgia? Turk J Osteoporos 2019;25:49-52.
  • 18. Zhang H, Wang J, Ying GS, et al. Diabetic retinopathy and renal function in Chinese type 2 diabetic patients. Int Urol Nephrol. 2014;46:1375-1381. doi:10.1007/s11255-014-0675-4
  • 19. Zhang X, Kumari N, Low S, et al. The association of serum creatinine and estimated glomerular fi ltration rate variability with diabetic retinopathy in Asians with type 2 diabetes: A nested case-control study. Diab Vasc Dis Res. 2018;15:548-558
  • 20. Cikrikcioglu MA, Erturk Z, Kilic E, et al. Endocan and albuminuria in type 2 diabetes mellitus. Renal failure. 2016;38:1647-53
  • 21. Bilir B, Ekiz Bilir B, Yilmaz I. Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients. Eur Rev Med Pharmacol Sci. 2016 Mar;20:892-8.
  • 22. Hu H, Jiang H, Ren H, et al. AGEs and chronic subclinical infl ammation in diabetes: disorders of immune system. Diabetes/metabolism research and reviews. 2015;31:127-37.
  • 23. Shalwala A, Lassalle P, Caires NF, et al. Elevation of Vitreous Endocan Levels in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2011;52:1295
  • 24. Arman Y, Akpinar TS, Kose M, et al. Effect of Glycemic Regulation on Endocan Levels in Patients With Diabetes: A Preliminary Study. Angiology. 2016 Mar;67:239-44. doi: 10.1177/0003319715585664. Epub 2015 May 12.
  • 25. Abu El-Asrar AM, Nawaz MI, De Hertogh G, et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Current eye research. 2015;40:321-31.
  • 26. Hainsworth DP, Bebu I, Aiello LP, et al. Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. 2019 Mar 4. pii: dc182308. doi: 10.2337/dc18-2308. [Epub ahead of print]
  • 27. Hatz K, Minder AE, Lehmann R, et al. The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensifi ed insulin therapy and its association with parameters of glucose control. Diabetes Res Clin Pract. 2019 Feb;148:234-239. doi: 10.1016/j.diabres.2019.01.016. Epub 2019 Jan 23.
  • 28. Long M, Wang C, Liu D. Glycated hemoglobin A1C and vitamin D and their association with diabetic retinopathy severity. Nutr Diabetes. 2017;7:e281.
  • 29. Andreasson R, Ekelund C, Landin-Olsson M, et al. HbA1c levels in children with type 1 diabetes and correlation to diabetic retinopathy. Journal of Pediatric Endocrinology and Metabolism.2018; 31: 369-374.
  • 30. Hwang IC, Bae JH, Kim JM. Relationship between body fat and diabetic retinopathy in patients with type 2 diabetes: a nationwide survey in Korea. Eye (Lond). 2019 Feb 13. doi: 10.1038/s41433-019-0352-z.
  • 31. Willermain F, Scifo L, Weber C, et al. Potential Interplay between Hyperosmolarity and Infl ammation on Retinal Pigmented Epithelium in Pathogenesis of Diabetic Retinopathy. Int J Mol Sci. 2018 Apr 2;19(4). pii: E1056. doi: 10.3390/ijms19041056.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.